文献速递消化系统肿瘤

Sotorasib用于既往接受过治疗的KRASG12C突变结直肠癌(CodeBreaK100):单臂2期试验的预设分析

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2021-12-15

这项单臂2期试验在33个中心的62例KRASG12C突变结直肠癌患者中评估每日一次口服960 mg sotorasib的疗效与安全性,客观缓解率为9.7%(6/62,95%CI 3.6-19.9),均为部分缓解;3级治疗相关不良事件发生率为10%,无致死性事件。

要点

  • 客观缓解率9.7%(6/62,95%CI 3.6-19.9),均为部分缓解
  • 3级治疗相关不良事件6例(10%),最常见为腹泻2例(3%)
  • 无致死性事件记录,严重治疗相关不良事件2例(3%)

核心结论

  • 9.7%的总体缓解率未达到预设基准,但每日一次口服sotorasib在这些经重度治疗且化疗难治的患者中显示出适度的抗肿瘤活性和可控的安全性。
  • Sotorasib正在与其他治疗联合评估,以提高潜在活性并克服潜在耐药机制。

研究设计与样本

  • 单臂2期试验,纳入KRASG12C突变晚期实体瘤成人患者,来自11个国家59个医疗中心。
  • 本分析仅呈现结直肠癌患者数据,来自9个国家33个医疗中心,这些患者须在氟尿嘧啶、奥沙利铂和伊立替康治疗后进展。
  • 患者每日一次口服sotorasib 960 mg,直至疾病进展、出现不可接受的不良事件、撤回知情同意或死亡。
  • 主要终点为盲态独立中心评估的客观缓解(完全或部分缓解)。
  • 截至2021年3月1日数据截止,62例KRASG12C突变结直肠癌患者于2019年8月14日至2020年5月21日入组并接受至少一剂sotorasib单药治疗。

主要发现

  • 62例患者中6例(9.7%,95%CI 3.6-19.9)观察到客观缓解,均为部分缓解。
  • 3级治疗相关不良事件发生于6例(10%)患者,最常见为腹泻(2例[3%])。
  • 4级治疗相关不良事件发生于1例(2%)患者(血肌酸磷酸激酶升高)。
  • 无致死性事件记录。
  • 严重治疗相关不良事件发生于2例(3%)患者(背痛和急性肾损伤)。

关键数值与推荐

  • 客观缓解率9.7%(6/62,95%CI 3.6-19.9)。
  • 3级治疗相关不良事件10%(6/62),其中腹泻3%(2/62)。
  • 4级治疗相关不良事件2%(1/62),为血肌酸磷酸激酶升高。
  • 严重治疗相关不良事件3%(2/62)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sotorasib, a specific, irreversible KRASG12C protein inhibitor, has shown monotherapy clinical activity in KRASG12C-mutated solid tumours, including colorectal cancer, in the CodeBreaK100 phase 1 trial. We aimed to investigate the activity and safety of sotorasib in phase 2 of the trial. METHODS: In this single-arm, phase 2 trial, adult patients with KRASG12C-mutated advanced solid tumours were enrolled, from 59 medical centres in 11 countries, if they were aged 18 years or older, had at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1, and had an Eastern Cooperative Oncology Group performance status of 1 or lower. Only data for patients with colorectal cancer, enrolled at 33 medical centres in nine countries, are presented from this basket trial. To be enrolled, the patients had to have progressed after receiving fluoropyrimidine, oxaliplatin, and irinotecan treatment. These patients were administered 960 mg sotorasib orally once per day until disease progression, development of unacceptable side-effects, withdrawal of consent, or death. The primary endpoint was objective response (complete or partial response) as assessed by blinded independent central review. Response was evaluated in patients who received at least one dose of sotorasib and had at least one measurable lesion at baseline; safety was evaluated in patients who received at least one dose of sotorasib. This analysis is a prespecified analysis triggered by the phase 2 colorectal cancer cohort. This study is registered with ClinicalTrials.gov, NCT03600883, and is active but no longer recruiting. FINDINGS: On March 1, 2021, at data cutoff, 62 patients with KRASG12C-mutant colorectal cancer had been enrolled between Aug 14, 2019, and May 21, 2020, and had received at least one dose of sotorasib monotherapy. Objective response was observed in six (9·7%, 95% CI 3·6-19·9) of 62 patients, all with partial response. Treatment-related adverse events at grade 3 occurred in six (10%) patients, the most common of which was diarrhoea (two [3%] of 62 patients), and at grade 4 occurred in one (2%) patient (blood creatine phosphokinase increase); no fatal events were recorded. Serious treatment-related adverse events occurred in two (3%) patients (back pain and acute kidney injury). INTERPRETATION: Although the 9·7% overall response rate did not reach the benchmark, oral administration of sotorasib once per day showed modest anti-tumour activity and manageable safety in these heavily pretreated chemorefractory patients. Sotorasib is under evaluation in combination with other therapeutics to increase potential activity and overcome potential resistance mechanisms. FUNDING: Amgen.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Fakih MG, Kopetz S, Kuboki Y, et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 2021. PMID: 34919824. doi:10.1016/S1470-2045(21)00605-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。